The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/Ib study of inavolisib (INAVO) + bevacizumab (BEV) or cetuximab (CETUX) for PIK3CA-mutated (mut) metastatic colorectal cancer (mCRC).
 
Marwan Fakih
Consulting or Advisory Role - Abbvie; Adagene; Bayer; BMS; Delcath Systems; Iterion Therapeutics; Janssen Research & Development; Merck; Microbial Machines; Mirati Therapeutics; Roche/Genentech; Summit Therapeutics; Taiho Pharmaceutical; Tempus; Totus Medicines; Xilio Therapeutics
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Eric Chen
Honoraria - AstraZeneca Canada; Eisai; GlaxoSmithKline; Merck; Pfizer; Roche; Takeda
Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Repare Therapeutics; Roche Canada
 
Keun-Wook Lee
Honoraria - Astellas Pharma; Bayer; Celltrion; Merck KGaA; MSD Oncology; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; BeiGene; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; PIN therapeutics; Takeda
Research Funding - ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avelos Therapeutics (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genome & Company (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IDRx (Inst); IgM Biosciences (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Jazz Pharmaceuticals (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Leap Therapeutics (Inst); Medicenna (Inst); MedPacto (Inst); Merck KGaA (Inst); Metafines (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Panolos Bioscience (Inst); Pfizer (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Torl Biotherapeutics (Inst); Trishula Therapeutics (Inst); Wellmarker Bio (Inst); Yuhan (Inst)
(OPTIONAL) Uncompensated Relationships - ALX Oncology
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Fosun Pharma; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Jun Gong
Honoraria - Agenus; Amgen; Astellas Pharma; AVEO; Basilea Pharmaceutical; Bayer; BeiGene; Clinical Congress Consultants; Eisai; Elsevier; EMD Serono; Exelixis; HalioDx; Incyte; Janssen Biotech; Natera; Pfizer; Pfizer/Myovant; QED Therapeutics; Seagen; Taiho Pharmaceutical
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AVEO; Basilea; Bayer; BeiGene; Caper Labs; Clinical Congress Consultants; Eisai; Elsevier; EMD Serono/Merck; Exelixis; HalioDx; Incyte; Janssen Biotech; MJH Life Sciences; Natera; OncLive/MJH Life Sciences; Pfizer; Pfizer/Myovant; QED Therapeutics; Seagen; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - PCT/US2021/043961 provisional patent on glutamine and cancer; U.S. Provisional Application Serial No. 63/315,895 on methylated ctDNA markers
 
Elena Elez
Honoraria - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagen; SERVIER; Takeda
Speakers' Bureau - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson & Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute; Roche; Rottapharm Biotech; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Agenus (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech, Therapeutics, S.L. (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim de España S.A. (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Enterome BioScience SA (Inst); Exelixis (Inst); Genentech (Inst); Gercor (Inst); GlaxoSmithKline (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); NuCana plc. (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagan; SERVIER; Takeda
 
Janet Lau
Employment - Genentech
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Jeaneen Venkatas, PhD, and Katie Wilson, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Vanessa Breton
Employment - Roche
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Jeaneen Venkatas, PhD, and Katie Wilson, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Omara Khan
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Olga Chertkova
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Saket Jain
Employment - Genentech
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Jeaneen Venkatas, PhD, and Katie Wilson, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Sae-Won Han
Consulting or Advisory Role - Abbvie; AstraZeneca; Natera
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeyondBio (Inst); Boryung (Inst); Cell Biotech (Inst); GC Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); Hengrui Pharmaceutical (Inst); IMBdx (Inst); Janssen (Inst); Jeil Pharmaceutical Co (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck KGaA (Inst); Mirati Therapeutics (Inst); MSD (Inst); Roche (Inst); Seagen (Inst)